Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genus plc (GENSF)
Basingstoke, GB
Genus plc is a global animal genetics company, with operations extending across North America, Latin America, the United Kingdom, broader Europe, the Middle East, Russia, Africa, and Asia. The firm organizes its business into three primary segments: Genus PIC, Genus ABS, and Genus Research and Development. Through its PIC brand, the company supplies breeding pigs and boar semen, enabling the production of swine with specific traits for pork processing. Furthermore, under the ABS, Genus, and Bovec labels, it provides bull semen and bovine embryos to facilitate the breeding of calves with targeted characteristics for dairy and beef output. Genus plc also extends specialized technical support to agricultural producers. Established in 1994, the company's headquarters are located in Basingstoke, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.02% | -6.29% | -16.60% | -11.62% | -11.24% | +16.79% | -11.57% | -55.17% | +36.55% | +1,453.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%+0.6% Q4'25: +101.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+108.3% ★ Q4'25: +350.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+9.8% ★ Q4'25: +5.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+7.3% ★ Q4'25: +10.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+7.1% ★ Q4'25: +15.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q4'25: +1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.84× Q4'25: 1.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 12 Rev. Ana. 1 EPS Ana. |
Jun 2027 12 Rev. Ana. 1 EPS Ana. |
Jun 2028 5 Rev. Ana. 1 EPS Ana. |
Jun 2029 10 Rev. Ana. 1 EPS Ana. |
Jun 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
398.50M
est: 619.71M (-35.7%)
|
388.30M
est: 531.43M (-26.9%)
|
459.10M
est: 583.16M (-21.3%)
|
470.30M
est: 628.50M (-25.2%)
|
488.50M
est: 617.24M (-20.9%)
|
551.40M
est: 645.15M (-14.5%)
|
574.30M
est: 788.33M (-27.2%)
|
593.40M
est: 686.38M (-13.5%)
|
689.70M
est: 879.18M (-21.6%)
|
668.80M
est: 670.48M (-0.3%)
|
672.80M
est: 675.28M (-0.4%)
|
663.74M
631.28M – 710.90M
-1.7% YoY
|
676.09M
612.51M – 732.95M
+1.9% YoY
|
690.80M
641.28M – 744.43M
+2.2% YoY
|
735.59M
682.87M – 792.70M
+6.5% YoY
|
755.45M
701.30M – 814.10M
+2.7% YoY
|
| EBITDA |
-38.50M
est: 81.07M (-147.5%)
|
51.40M
est: 69.52M (-26.1%)
|
57.70M
est: 76.29M (-24.4%)
|
31.40M
est: 82.22M (-61.8%)
|
65.50M
est: 80.75M (-18.9%)
|
68.00M
est: 84.40M (-19.4%)
|
82.30M
est: 103.13M (-20.2%)
|
79.80M
est: 89.80M (-11.1%)
|
87.50M
est: 115.02M (-23.9%)
|
73.70M
est: 87.71M (-16.0%)
|
93.70M
est: 88.34M (+6.1%)
|
86.83M
82.59M – 93.00M
-1.7% YoY
|
88.45M
80.13M – 95.89M
+1.9% YoY
|
90.37M
83.89M – 97.39M
+2.2% YoY
|
96.23M
89.33M – 103.70M
+6.5% YoY
|
98.83M
91.75M – 106.50M
+2.7% YoY
|
| EBIT |
-50.90M
est: 40.55M (-225.5%)
|
37.20M
est: 34.78M (+7.0%)
|
44.80M
est: 38.16M (+17.4%)
|
12.20M
est: 41.13M (-70.3%)
|
44.30M
est: 40.39M (+9.7%)
|
45.40M
est: 42.22M (+7.5%)
|
60.30M
est: 51.59M (+16.9%)
|
56.60M
est: 44.91M (+26.0%)
|
43.80M
est: 57.53M (-23.9%)
|
26.80M
est: 43.87M (-38.9%)
|
49.00M
est: 44.19M (+10.9%)
|
43.43M
41.31M – 46.52M
-1.7% YoY
|
44.24M
40.08M – 47.96M
+1.9% YoY
|
45.20M
41.96M – 48.71M
+2.2% YoY
|
48.13M
44.68M – 51.87M
+6.5% YoY
|
49.43M
45.89M – 53.27M
+2.7% YoY
|
| Net Income |
39.90M
est: 36.40M (+9.6%)
|
49.30M
est: 38.27M (+28.8%)
|
32.80M
est: 43.72M (-25.0%)
|
42.70M
est: 49.47M (-13.7%)
|
7.80M
est: 48.67M (-84.0%)
|
35.30M
est: 52.90M (-33.3%)
|
47.30M
est: 66.51M (-28.9%)
|
40.90M
est: 54.63M (-25.1%)
|
33.30M
est: 53.44M (-37.7%)
|
7.90M
est: 43.80M (-82.0%)
|
19.30M
est: 52.42M (-63.2%)
|
68.78M
62.37M – 75.72M
+31.2% YoY
|
67.90M
61.57M – 74.75M
-1.3% YoY
|
74.21M
67.29M – 81.70M
+9.3% YoY
|
87.32M
79.18M – 96.13M
+17.7% YoY
|
85.60M
77.63M – 94.24M
-2.0% YoY
|
| SGA |
64.30M
est: 76.49M (-15.9%)
|
71.10M
est: 65.59M (+8.4%)
|
77.90M
est: 71.98M (+8.2%)
|
81.60M
est: 77.58M (+5.2%)
|
71.90M
est: 76.19M (-5.6%)
|
88.00M
est: 79.63M (+10.5%)
|
96.70M
est: 97.30M (-0.6%)
|
89.40M
est: 84.72M (+5.5%)
|
93.10M
est: 108.52M (-14.2%)
|
109.10M
est: 82.76M (+31.8%)
|
—
est: 83.35M (-100.0%)
|
81.93M
77.92M – 87.75M
-1.7% YoY
|
83.45M
75.60M – 90.47M
+1.9% YoY
|
85.26M
79.15M – 91.88M
+2.2% YoY
|
90.79M
84.29M – 97.84M
+6.5% YoY
|
93.25M
86.56M – 100.48M
+2.7% YoY
|
| EPS |
0.66
est: 0.54 (+21.2%)
|
0.81
est: 0.57 (+41.5%)
|
0.54
est: 0.65 (-17.5%)
|
0.70
est: 0.74 (-5.4%)
|
0.12
est: 0.73 (-83.5%)
|
0.54
est: 0.79 (-31.8%)
|
0.73
est: 1.00 (-26.6%)
|
0.63
est: 0.82 (-22.9%)
|
0.51
est: 0.80 (-36.2%)
|
0.12
est: 0.66 (-81.7%)
|
0.25
est: 0.78 (-68.1%)
|
1.03
0.93 – 1.13
+31.2% YoY
|
1.02
0.92 – 1.12
-1.3% YoY
|
1.11
1.01 – 1.22
+9.3% YoY
|
1.31
1.18 – 1.44
+17.7% YoY
|
1.28
1.16 – 1.41
-2.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 2/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jorgen Kokke | Chief Executive Officer & Executive Director | 3M | male |
| Andrew Paul Russell | Chief Financial Officer & Executive Director | 1M | male |
| Elena Rice | Head of R&D and Chief Scientific Officer | — | — |
| Janet Duane | Group Financial Controller | — | female |
| Jim Low | Chief Operating Officer of Genus ABS | — | male |
| Lucie Mary Katja Grant | Group General Counsel & Company Secretary | — | female |
| Mark Birri | Chief Corporate Development Officer | — | male |
| Matt Culbertson | Chief Operating Officer | — | — |
| Angelle R. Rosata | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GENSF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
